Closing the Funding Gap in Cancer Research
Lung cancer claims more lives each year than breast, colon and prostate cancers combined, yet lung cancer receives disproportionately less government funding per cancer death than other types of cancer. This means that private funding for lung cancer research that is focused on finding a cure is vital to saving lives.
A Breath of Hope Lung Foundation raises funds to support outreach and A Breath of Hope Research Fellows, America’s most promising young researchers who have been identified through a national RFP process. Retaining young talent in the field of lung cancer research is critical to changing outcomes.
Find out more about the winners of the 2016 ABOH Research Fellowships:
– ABOHLF Women & Lung Cancer Award: Dr. Amanda Redig
– Larry Benjamin Early Detection Award: Dr. Jun-Chieh (James) Tsay.
In previous years: our 2014 ABOH Research Fellows, Dr. Kamesh Bikkavilli and Dr. Manish Patel.
Another addition to ABOH’s Lung Cancer Research Program are our special “Named Research Grants”. This program enables donors to fund part or all of a research fellowship in their name or in memory or honor of a loved one.
Please join us, your donations will help us beat lung cancer!
Research Facts & Underfunding
- Over 50% of new cases are non-smokers or former smokers, many of whom quit decades ago. One in five women and one in twelve men diagnosed with lung cancer have never smoked.
- 160,000 Americans die annually, including 2500 Minnesotans. More than 226,000 people are diagnosed with lung and bronchus cancer in the US each year.
- Less money is spent on lung cancer research than most other cancers. In recent years, the National Cancer Institute estimated that our government spent over $11,000 per breast cancer death for research, and $1100 per lung cancer death. Lung cancer takes almost twice as many women as breast cancer.
- Lack of funding drives talented young researchers away from lung cancer, despite their interest and commitment.
- Lung cancer kills more people than breast, prostate and colon cancers combined, yet receives less funding than each (see graph below).